ABSTRACT
Antiretroviral therapy (ART) has brought the HIV/AIDS epidemic under control, but a curative strategy for viral eradication is still needed. The cessation of ART results in rapid viral rebound from latently infected CD4+ T cells, showing that control of viral replication alone does not fully restore immune function, nor does it eradicate viral reservoirs. With a better understanding of factors and mechanisms that promote viral latency, current approaches are primarily focused on the permanent silencing of latently infected cells ("block and lock") or reactivating HIV-1 gene expression in latently infected cells, in combination with immune restoration strategies to eliminate HIV infected cells from the host ("shock and kill"). In this review, we provide a summary of the current, most promising approaches for HIV-1 cure strategies, including an analysis of both latency-promoting agents (LPA) and latency-reversing agents (LRA) that have shown promise in vitro, ex vivo, and in human clinical trials to reduce the HIV-1 reservoir.
Subject(s)
HIV Infections , HIV Seropositivity , HIV-1 , Humans , Virus Latency , Virus Replication , HIV-1/physiology , CD4-Positive T-Lymphocytes , Virus ActivationABSTRACT
Several studies have emphasized the importance of an early, highly neutralizing antibody response in the clearance of Hepatitis C virus (HCV) infection. The envelope glycoprotein E2 is a major target for HCV neutralizing antibodies. Here, we compared antibody responses in mice immunized with native soluble E2 (sE2) from the H77 1a isolate coupled with different adjuvants or combinations of adjuvants. Adjuvanting sE2 with Freund's, monophosphoryl lipid A (MPL), cytosine phosphorothioate guanine oligodeoxynucleotide (CpG ODN), or alpha-galactosylceramide (αGalCer) derivatives elicited only moderate antibody responses. In contrast, immunizations with sE2 and QuilA elicited exceptionally high anti-E2 antibody titers. Sera from these mice effectively neutralized HCV pseudoparticles (HCVpp) 1a entry. Moreover, the combination of QuilA and CpG ODN further enhanced neutralizing antibody titers wherein cross-neutralization of HCVpp 4 was observed. We conclude that the combination of QuilA and CpG ODN is a promising adjuvant combination that should be further explored for the development of an HCV subunit vaccine. Our work also emphasizes that the ideal combination of adjuvant and immunogen has to be determined empirically.
Subject(s)
Adjuvants, Immunologic/pharmacology , Hepatitis C Antibodies/blood , Oligodeoxyribonucleotides/immunology , Saponins/immunology , Viral Envelope Proteins/immunology , Viral Hepatitis Vaccines/immunology , Animals , Antibodies, Neutralizing/blood , Cell Line, Tumor , Female , Galactosylceramides/immunology , Hepacivirus/immunology , Humans , Mice , Mice, Inbred BALB C , Neutralization Tests , Quillaja SaponinsABSTRACT
BACKGROUND & AIMS: Hepatitis C virus (HCV) infection is a challenge to prevent and treat because of the rapid development of drug resistance and escape. Viral entry is required for initiation, spread, and maintenance of infection, making it an attractive target for antiviral strategies. The tight junction protein claudin-1 (CLDN1) has been shown to be required for entry of HCV into the cell. METHODS: Using genetic immunization, we produced 6 monoclonal antibodies against the host entry factor CLDN1. The effects of antibodies on HCV infection were analyzed in human cell lines and primary human hepatocytes. RESULTS: Competition and binding studies demonstrated that antibodies interacted with conformational epitopes of the first extracellular loop of CLDN1; binding of these antibodies required the motif W(30)-GLW(51)-C(54)-C(64) and residues in the N-terminal third of CLDN1. The monoclonal antibodies against CLDN1 efficiently inhibited infection by HCV of all major genotypes as well as highly variable HCV quasispecies isolated from individual patients. Furthermore, antibodies efficiently blocked cell entry of highly infectious escape variants of HCV that were resistant to neutralizing antibodies. CONCLUSIONS: Monoclonal antibodies against the HCV entry factor CLDN1 might be used to prevent HCV infection, such as after liver transplantation, and might also restrain virus spread in chronically infected patients.
Subject(s)
Antibodies, Monoclonal/pharmacology , Antiviral Agents/pharmacology , Hepacivirus/drug effects , Hepatitis C/prevention & control , Hepatocytes/drug effects , Membrane Proteins/antagonists & inhibitors , Virus Internalization/drug effects , Animals , Antibodies, Monoclonal/metabolism , Antibodies, Monoclonal/toxicity , Antibody Specificity , Antiviral Agents/metabolism , Antiviral Agents/toxicity , Binding Sites, Antibody , Binding, Competitive , CHO Cells , Cell Survival/drug effects , Claudin-1 , Cricetinae , Cricetulus , Dose-Response Relationship, Drug , Epitopes , Genotype , Hep G2 Cells , Hepacivirus/genetics , Hepacivirus/pathogenicity , Hepatitis C/immunology , Hepatocytes/immunology , Hepatocytes/virology , Humans , Membrane Proteins/immunologyABSTRACT
Claudin-1, a component of tight junctions between liver hepatocytes, is a hepatitis C virus (HCV) late-stage entry cofactor. To investigate the structural and functional roles of various claudin-1 domains in HCV entry, we applied a mutagenesis strategy. Putative functional intracellular claudin-1 domains were not important. However, we identified seven novel residues in the first extracellular loop that are critical for entry of HCV isolates drawn from six different subtypes. Most of the critical residues belong to the highly conserved claudin motif W(30)-GLW(51)-C(54)-C(64). Alanine substitutions of these residues did not impair claudin-1 cell surface expression or lateral protein interactions within the plasma membrane, including claudin-1-claudin-1 and claudin-1-CD81 interactions. However, these mutants no longer localized to cell-cell contacts. Based on our observations, we propose that cell-cell contacts formed by claudin-1 may generate specialized membrane domains that are amenable to HCV entry.
Subject(s)
Cell Communication , Hepacivirus/physiology , Membrane Proteins/metabolism , Virus Internalization , Amino Acid Motifs , Cell Line , Cell Membrane/metabolism , Claudin-1 , Extracellular Space/metabolism , Humans , Membrane Proteins/chemistry , Membrane Proteins/genetics , Molecular Sequence Data , Mutation/geneticsABSTRACT
Hepatitis C virus (HCV) is a major cause of liver disease in humans. The CD81 tetraspanin is necessary but not sufficient for HCV penetration into hepatocytes, and it was recently reported that the tight junction protein claudin-1 is a critical HCV entry cofactor. Here, we confirm the role of claudin-1 in HCV entry. In addition, we show that claudin-6 and claudin-9 expressed in CD81(+) cells also enable the entry of HCV pseudoparticles derived from six of the major genotypes. Whereas claudin-1, -6, and -9 function equally well as entry cofactors in endothelial cells, claudin-1 is more efficient in hepatoma cells. This suggests that additional cellular factors modulate the ability of claudins to function as HCV entry cofactors. Our work has generated novel and essential means to investigate the mechanism of HCV penetration into hepatocytes and the role of the claudin protein family in HCV dissemination, replication, and pathogenesis.
Subject(s)
Hepacivirus/physiology , Membrane Proteins/physiology , Receptors, Virus/physiology , Virus Internalization , Cell Line , Claudin-1 , Claudins , Endothelial Cells/virology , Gene Silencing , Hepatocytes/virology , Humans , RNA, Small Interfering/genetics , RNA, Small Interfering/metabolismABSTRACT
We studied the antiviral activity of carbohydrate-binding agents (CBAs), including several plant lectins and the non-peptidic small-molecular-weight antibiotic pradimicin A (PRM-A). These agents efficiently prevented hepatitis C virus (HCV) and human immunodeficiency virus type 1 (HIV-1) infection of target cells by inhibiting the viral entry. CBAs were also shown to prevent HIV and HCV capture by DC-SIGN-expressing cells. Surprisingly, infection by other enveloped viruses such as herpes simplex viruses, respiratory syncytial virus and parainfluenza-3 virus was not inhibited by these agents pointing to a high degree of specificity. Mannan reversed the antiviral activity of CBAs, confirming their association with viral envelope-associated glycans. In contrast, polyanions such as dextran sulfate-5000 and sulfated polyvinylalcohol inhibited HIV entry but were devoid of any activity against HCV infection, indicating that they act through a different mechanism. CBAs could be considered as prime drug leads for the treatment of chronic viral infections such as HCV by preventing viral entry into target cells. They may represent an attractive new option for therapy of HCV/HIV coinfections. CBAs may also have the potential to prevent HCV/HIV transmission.
Subject(s)
Anions/pharmacology , Antiviral Agents/pharmacology , HIV/physiology , Hepacivirus/physiology , Animals , Carbohydrate Metabolism , Cell Line, Tumor , HIV/drug effects , HIV-1/drug effects , HIV-1/physiology , HIV-2/drug effects , HIV-2/physiology , Hepacivirus/drug effects , Humans , T-Lymphocytes/drug effects , T-Lymphocytes/virology , Virus ReplicationABSTRACT
Hepatitis C virus (HCV) is a major human pathogen that causes serious liver disease, including cirrhosis and hepatocellular carcinoma. The primary target cells of HCV are hepatocytes, and entry is restricted by interactions of the envelope glycoproteins, E1 and E2, with cellular receptors. E1 and E2 form noncovalently linked heterodimers and are heavily glycosylated. Glycans contribute to protein folding and transport as well as protein function. In addition, glycans associated with viral envelopes mask important functional domains from the immune system and attenuate viral immunogenicity. Here, we explored the role of N- and O-linked glycans on E2, which is the receptor binding subunit of the HCV envelope. We identified a number of glycans that are critical for viral entry. Importantly, we showed that the removal of several glycans significantly increased the inhibition of entry by sera from HCV-positive individuals. Only some of the glycans that affected entry and neutralization were also important for CD81 binding. Our results show that HCV envelope-associated glycans play a crucial role in masking functionally important regions of E2 and suggest a new strategy for eliciting highly neutralizing antibodies against this virus.
Subject(s)
Antigens, CD/immunology , Hepacivirus/immunology , Polysaccharides/metabolism , Viral Envelope Proteins/metabolism , Virus Internalization , Animals , Hepatitis C/metabolism , Hepatitis C Antigens/chemistry , Hepatitis C Antigens/immunology , Humans , Polysaccharides/chemistry , Tetraspanin 28 , Viral Envelope Proteins/chemistryABSTRACT
Hepatitis C virus (HCV) is a major human pathogen associated with life-threatening liver disease. Entry into hepatocytes requires CD81 and a putative second receptor. In this study, we elucidated the postreceptor attachment stages of HCV entry using HCV pseudoparticles (HCVpp) as a model system. By means of dominant-negative mutants and short interfering RNAs of various cellular proteins, we showed that HCVpp enter via clathrin-coated vesicles and require delivery to early but not to late endosomes. However, the kinetics of HCV envelope glycoprotein-mediated fusion are delayed compared to those of other viruses that enter in early endosomes. Entry of HCVpp can be efficiently blocked by bafilomycin A1, which neutralizes the pH in early endosomes and impairs progression of endocytosis beyond this stage. However, low-pH exposure of bafilomycin A1-treated target cells does not induce entry of HCVpp at the plasma membrane or in the early stages of endocytosis. These observations indicate that, subsequent to internalization, HCVpp entry necessitates additional, low-pH-dependent interactions, modifications, or trafficking, and that these events are irreversibly disrupted by bafilomycin A1 treatment.
Subject(s)
Clathrin/metabolism , Endocytosis/physiology , Endosomes/metabolism , Endosomes/physiology , Hepacivirus/physiology , Cell Line, Tumor , Endocytosis/drug effects , Endosomes/virology , Gene Expression Regulation, Viral/drug effects , Hepacivirus/metabolism , Humans , Macrolides/pharmacologyABSTRACT
L-SIGN is a C-type lectin that is expressed on liver sinusoidal endothelial cells. Capture of Hepatitis C virus (HCV) by this receptor results in trans-infection of hepatoma cells. L-SIGN alleles have been identified that encode between three and nine tandem repeats of a 23 residue stretch in the juxtamembrane oligomerization domain. Here, it was shown that these repeat-region isoforms are expressed at the surface of mammalian cells and variably bind HCV envelope glycoprotein E2 and HCV pseudoparticles. Differences in binding were reflected in trans-infection efficiency, which was highest for isoform 7 and lowest for isoform 3. These findings provide a molecular mechanism whereby L-SIGN polymorphism could influence the establishment and progression of HCV infection.
Subject(s)
Cell Adhesion Molecules/physiology , Hepacivirus/pathogenicity , Hepatitis C/etiology , Lectins, C-Type/physiology , Receptors, Cell Surface/physiology , Receptors, Virus/physiology , Alleles , Carcinoma, Hepatocellular/virology , Cell Adhesion Molecules/genetics , HeLa Cells , Hepatitis C/genetics , Hepatitis C/virology , Hepatocytes/virology , Humans , Lectins, C-Type/genetics , Minisatellite Repeats , Protein Isoforms/genetics , Protein Isoforms/physiology , Receptors, Cell Surface/genetics , Receptors, Virus/genetics , Transfection , Viral Envelope Proteins/physiologyABSTRACT
HIV-1 coreceptors are attractive targets for novel antivirals. Here, inhibition of entry by two classes of CCR5 antagonists was investigated. We confirmed previous findings that HIV-1 isolates vary greatly in their sensitivity to small molecule inhibitors of CCR5-mediated entry, SCH-C and TAK-779. In contrast, an anti-CCR5 monoclonal antibody (PA14) similarly inhibited entry of diverse viral isolates. Sensitivity to small molecules was V3 loop-dependent and inversely proportional to the level of gp120 binding to CCR5. Moreover, combinations of the MAb and small molecules were highly synergistic in blocking HIV-1 entry, suggesting different mechanisms of action. This was confirmed by time course of inhibition experiments wherein the PA14 MAb and small molecules were shown to inhibit temporally distinct stages of CCR5 usage. We propose that small molecules inhibit V3 binding to the second extracellular loop of CCR5, whereas PA14 preferentially inhibits subsequent events such as CCR5 recruitment into the fusion complex or conformational changes in the gp120-CCR5 complex that trigger fusion. Importantly, our findings suggest that combinations of CCR5 inhibitors with different mechanisms of action will be central to controlling HIV-1 infection and slowing the emergence of resistant strains.
Subject(s)
Antibodies, Monoclonal/administration & dosage , CCR5 Receptor Antagonists , HIV-1/pathogenicity , Amides/administration & dosage , Anti-HIV Agents/administration & dosage , Cyclic N-Oxides/administration & dosage , Drug Synergism , HIV Envelope Protein gp120/genetics , HIV Envelope Protein gp120/physiology , HIV Infections/therapy , HIV Infections/virology , HIV-1/genetics , HIV-1/physiology , HeLa Cells , Humans , In Vitro Techniques , Oximes , Peptide Fragments/genetics , Peptide Fragments/physiology , Piperidines/administration & dosage , Pyridines/administration & dosage , Quaternary Ammonium Compounds/administration & dosage , Receptors, CCR5/immunology , Recombinant Proteins/genetics , Recombinant Proteins/metabolismABSTRACT
The CD81 tetraspanin was first identified as a hepatitis C virus (HCV) receptor by its ability to bind the soluble ectodomain of envelope glycoprotein E2 (sE2). More recently, it has been suggested that CD81 is necessary but not sufficient for HCV entry into target cells. Here we present further evidence that putative human hepatocyte-specific factors act in concert with CD81 to mediate sE2 binding and HCV pseudoparticle (HCVpp) entry. Moreover, we show that CD81-mediated HCVpp entry entails E2 binding to residues in the large extracellular loop as well as molecular events mediated by the transmembrane and intracellular domains of CD81. The concept that CD81 receptor function progresses in stages is further supported by our finding that anti-CD81 monoclonal antibodies inhibit HCVpp entry by different mechanisms. The half-life of CD81-HCVpp binding was determined to be approximately 17 min, and we propose that binding is followed by CD81 oligomerization, partitioning into cholesterol-rich membrane domains, or other, lateral protein-protein interactions. This results in the formation of a receptor-virus complex that undergoes endocytosis and pH-dependent membrane fusion.
Subject(s)
Antigens, CD/physiology , Hepacivirus/physiology , Hepacivirus/pathogenicity , Virion/physiology , 3T3 Cells , Amino Acid Sequence , Animals , Antibodies, Monoclonal , Antigens, CD/biosynthesis , Antigens, CD/immunology , Cell Line, Tumor , Cell Membrane/metabolism , Cell Membrane/virology , Extracellular Space/metabolism , Extracellular Space/virology , Gene Expression Regulation, Viral , Humans , Intracellular Fluid/metabolism , Intracellular Fluid/virology , Mice , Molecular Sequence Data , Protein Binding , Protein Structure, Tertiary , Tetraspanin 28 , U937 Cells , Viral Envelope Proteins/metabolism , Virion/pathogenicityABSTRACT
The CC-chemokine receptor 5 (CCR5) is the major coreceptor for macrophage-tropic (R5) HIV-1 strains. Several small molecule inhibitors of CCR5 that block chemokine binding and HIV-1 entry are being evaluated as drug candidates. Here we define how CCR5 antagonists TAK-779, AD101 (SCH-350581) and SCH-C (SCH-351125), which inhibit HIV-1 entry, interact with CCR5. Using a mutagenesis approach in combination with a viral entry assay to provide a direct functional read out, we tested predictions based on a homology model of CCR5 and analyzed the functions of more than 30 amino acid residues. We find that a key set of aromatic and aliphatic residues serves as a hydrophobic core for the ligand binding pocket, while E283 is critical for high affinity interaction, most likely by acting as the counterion for a positively charged nitrogen atom common to all three inhibitors. These results provide a structural basis for understanding how specific antagonists interact with CCR5, and may be useful for the rational design of new, improved CCR5 ligands.
Subject(s)
HIV Fusion Inhibitors/metabolism , Receptors, CCR5/metabolism , Amides/metabolism , Binding Sites/genetics , Cell Line , Cyclic N-Oxides/metabolism , HIV-1/growth & development , Humans , Models, Molecular , Molecular Structure , Mutagenesis, Site-Directed , Oximes , Piperidines/metabolism , Protein Structure, Secondary , Pyridines/metabolism , Quaternary Ammonium Compounds/metabolism , Receptors, CCR5/geneticsABSTRACT
CXCR4 is one of two physiologically relevant human immunodeficiency type 1 (HIV-1) entry coreceptors. Studies of CXCR4 mutants have not clearly identified the determinants of coreceptor function and specificity. We therefore used a panel of monoclonal antibodies to further elucidate CXCR4 expression, structure, and function. Our findings show the existence of conformational subpopulations of CXCR4 that are in equilibrium on the cell surface but are not cell type specific as previously reported. HIV-1 X4 isolates can interact with multiple CXCR4 conformations in order to gain entry into target cells.
Subject(s)
Antibodies, Monoclonal/immunology , Epitope Mapping , HIV-1/pathogenicity , Receptors, CXCR4/chemistry , Receptors, CXCR4/immunology , Antibodies, Monoclonal/metabolism , Cell Line , HIV-1/metabolism , HeLa Cells , Humans , Point Mutation , Protein Conformation , Receptors, CXCR4/genetics , Receptors, CXCR4/metabolism , T-LymphocytesABSTRACT
Target cell tropism of enveloped viruses is regulated by interactions between viral and cellular factors during transmission, dissemination, and replication within the host. Binding of viral envelope glycoproteins to specific cell-surface receptors determines susceptibility to viral entry. However, a number of cell-surface molecules bind viral envelope glycoproteins without mediating entry. Instead, they serve as capture receptors that disseminate viral particles to target organs or susceptible cells. We and others recently demonstrated that the C type lectins L-SIGN and DC-SIGN capture hepatitis C virus (HCV) by specific binding to envelope glycoprotein E2. In this study, we use an entry assay to demonstrate that HCV pseudoviruses captured by L-SIGN+ or DC-SIGN+ cells efficiently transinfect adjacent human liver cells. Virus capture and transinfection require internalization of the SIGN-HCV pseudovirus complex. In vivo, L-SIGN is largely expressed on endothelial cells in liver sinusoids, whereas DC-SIGN is expressed on dendritic cells. Capture of circulating HCV particles by these SIGN+ cells may facilitate virus infection of proximal hepatocytes and lymphocyte subpopulations and may be essential for the establishment of persistent infection.
Subject(s)
Cell Adhesion Molecules/metabolism , Hepacivirus/metabolism , Hepatocytes/virology , Lectins, C-Type/metabolism , Receptors, Cell Surface/metabolism , Viral Envelope Proteins/metabolism , Antibodies, Monoclonal/chemistry , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/pharmacology , Antigens, CD/chemistry , Antigens, CD/immunology , Cell Line , Chloroquine/pharmacology , Dendritic Cells/metabolism , Dendritic Cells/virology , HeLa Cells , Hepacivirus/genetics , Hepacivirus/pathogenicity , Hepatocytes/metabolism , Humans , Liver/cytology , Liver/metabolism , Liver/virology , Mannans/chemistry , Mannans/immunology , Mannans/pharmacology , Receptors, Virus/chemistry , Receptors, Virus/metabolism , Tetraspanin 28 , Transfection , Viral Envelope Proteins/genetics , Viral Envelope Proteins/immunologyABSTRACT
Hepatitis C virus (HCV) envelope glycoproteins E1/E2 can pseudotype retroviral particles and efficiently mediate entry into target cells. Using this experimental system, we determined HCV tropism for different cell types. Only primary hepatocytes and one hepatoma cell line were susceptible to HCV pseudovirus entry, which could be inhibited by sera from HCV-infected individuals. Furthermore, expression of the putative HCV receptor CD81 on nonpermissive human hepatic but not murine cells enabled HCV pseudovirus entry. Importantly, inhibition of viral entry by an anti-CD81 mAb occurred at a step following HCV attachment to target cells. Our results indicate that CD81 functions as a post-attachment entry coreceptor and that other cellular factors act in concert with CD81 to mediate HCV binding and entry into hepatocytes.
Subject(s)
Antigens, CD/physiology , Hepacivirus/physiology , Receptors, Virus/physiology , Cell Line, Tumor , Humans , Membrane Fusion/physiology , Tetraspanin 28ABSTRACT
Hepatitis C virus (HCV) is a positive-strand RNA virus that replicates exclusively in the cytoplasm of infected cells. The viral envelope glycoproteins, E1 and E2, appear to be retained in the endoplasmic reticulum, where viral budding is thought to occur. Surprisingly, we found that the expression system used to generate HCV envelope glycoproteins influences their subcellular localization and processing. These findings have important implications for optimizing novel HCV fusion and entry assays as well as for budding and virus particle formation.
Subject(s)
Cell Membrane/metabolism , Hepacivirus/pathogenicity , Introns , Viral Envelope Proteins/metabolism , Viral Structural Proteins/metabolism , Base Sequence , Dimerization , HeLa Cells , Hepacivirus/genetics , Hepacivirus/metabolism , Humans , Molecular Sequence Data , Sequence Deletion , Viral Envelope Proteins/genetics , Viral Structural Proteins/geneticsABSTRACT
Human immunodeficiency virus type 1 (HIV-1) entry is mediated by the consecutive interaction of the envelope glycoprotein gp120 with CD4 and a coreceptor such as CCR5 or CXCR4. The CCR5 coreceptor is used by the most commonly transmitted HIV-1 strains that often persist throughout the course of infection. Compounds targeting CCR5-mediated entry are a novel class of drugs being developed to treat HIV-1 infection. In this study, we have identified the mechanism of action of two inhibitors of CCR5 function, SCH-350581 (AD101) and SCH-351125 (SCH-C). AD101 is more potent than SCH-C at inhibiting HIV-1 replication in primary lymphocytes, as well as viral entry and gp120 binding to cell lines. Both molecules also block the binding of several anti-CCR5 monoclonal antibodies that recognize epitopes in the second extracellular loop of CCR5. Alanine mutagenesis of the transmembrane domain of CCR5 suggests that AD101 and SCH-C bind to overlapping but nonidentical sites within a putative ligand-binding cavity formed by transmembrane helices 1, 2, 3, and 7. We propose that the binding of small molecules to the transmembrane domain of CCR5 may disrupt the conformation of its extracellular domain, thereby inhibiting ligand binding to CCR5.
Subject(s)
CCR5 Receptor Antagonists , Cyclic N-Oxides/pharmacology , HIV-1/drug effects , HIV-1/pathogenicity , Piperidines , Pyridines/pharmacology , Amino Acid Sequence , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/metabolism , CD4-Positive T-Lymphocytes/virology , Cells, Cultured , HIV Envelope Protein gp120/metabolism , Humans , Membrane Fusion , Models, Molecular , Molecular Sequence Data , Oximes , Pyridines/chemistry , Receptors, CCR5/chemistry , Receptors, CCR5/genetics , Receptors, CCR5/metabolism , Virus ReplicationABSTRACT
Hepatitis C virus (HCV) infects nearly 3% of the population of the world and is a major cause of liver disease. However, the mechanism whereby the virus targets the liver for infection remains unknown, because none of the putative cellular receptors for HCV are both expressed specifically in the liver and capable of binding HCV envelope glycoproteins. Liver/lymph node-specific intercellular adhesion molecule-3-grabbing integrin (L-SIGN) is a calcium-dependent lectin expressed on endothelial cells of liver and lymph nodes. Dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN), a homologous molecule expressed on dendritic cells, binds HIV and promotes infection. By using a virus-binding assay, we demonstrate that L-SIGN and DC-SIGN specifically bind naturally occurring HCV present in the sera of infected individuals. Further studies demonstrate that binding is mediated by the HCV envelope glycoprotein E2 and is blocked by specific inhibitors, including mannan, calcium chelators, and Abs to the lectin domain of the SIGN molecules. Thus, L-SIGN represents a liver-specific receptor for HCV, and L-SIGN and DC-SIGN may play important roles in HCV infection and immunity.
Subject(s)
Cell Adhesion Molecules/physiology , Hepacivirus/pathogenicity , Hepatitis C/virology , Lectins, C-Type/physiology , Liver/virology , Receptors, Cell Surface/physiology , Receptors, Virus/physiology , Base Sequence , Binding Sites , Cell Adhesion Molecules/genetics , DNA, Complementary/genetics , DNA, Viral/genetics , HeLa Cells , Hepacivirus/genetics , Hepacivirus/physiology , Humans , In Vitro Techniques , Lectins, C-Type/genetics , RNA, Viral/genetics , Receptors, Cell Surface/genetics , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Viral Envelope Proteins/genetics , Viral Envelope Proteins/physiologyABSTRACT
Human immunodeficiency virus type 1 envelope glycoprotein gp120 interacts with CD4 and the CCR5 coreceptor in order to mediate viral entry. A CD4-induced surface on gp120, primarily composed of residues in the V3 loop and the C4 domain, interacts with CCR5. In the present study, we generated envelope glycoproteins comprising chimeric V3 loops and/or V3 loops with deletions and studied their binding to CCR5 amino-terminal domain (Nt)-based sulfopeptides and cell surface CCR5, as well as their ability to mediate viral entry. We thus delineated two functionally distinct domains of the V3 loop, the V3 stem and the V3 crown. The V3 stem alone mediates soluble gp120 binding to the CCR5 Nt. In contrast, both the V3 stem and crown are required for soluble gp120 binding to cell surface CCR5. Within the context of a virion, however, the V3 crown alone determines coreceptor usage. Our data support a two-site gp120-CCR5 binding model wherein the V3 crown and stem interact with distinct regions of CCR5 in order to mediate viral entry.
Subject(s)
HIV Envelope Protein gp120/chemistry , HIV Envelope Protein gp120/metabolism , HIV-1/pathogenicity , Peptide Fragments/chemistry , Peptide Fragments/metabolism , Receptors, CCR5/metabolism , Amino Acid Sequence , Binding Sites , Cell Line , Gene Deletion , HIV Envelope Protein gp120/genetics , Humans , Molecular Sequence Data , Peptide Fragments/genetics , Peptides/chemistry , Peptides/metabolism , Receptors, CCR5/chemistry , Recombinant Fusion Proteins , Sulfur/chemistry , TransfectionABSTRACT
CCR5 and CXCR4 usage has been studied extensively with a variety of clade B human immunodeficiency virus type 1 (HIV-1) isolates. The determinants of CCR5 coreceptor function are remarkably consistent, with a region critical for fusion and entry located in the CCR5 amino-terminal domain (Nt). In particular, negatively charged amino acids and sulfated tyrosines in the Nt are essential for gp120 binding to CCR5. The same types of residues are important for CXCR4-mediated viral fusion and entry, but they are dispersed throughout the extracellular domains of CXCR4, and their usage is isolate dependent. Here, we report on the determinants of CCR5 and CXCR4 coreceptor function for a panel of non-clade B isolates that are responsible for the majority of new HIV-1 infections worldwide. Consistent with clade B isolates, CXCR4 usage remains isolate dependent and is determined by the overall content of negatively charged and tyrosine residues. Residues in the Nt of CCR5 that are important for fusion and entry of clade B isolates are also important for the entry of all non-clade B HIV-1 isolates that we tested. Surprisingly, we found that in contrast to clade B isolates, a cluster of residues in the second extracellular loop of CCR5 significantly affects fusion and entry of all non-clade B isolates tested. This points to a different mechanism of CCR5 usage by these viruses and may have important implications for the development of HIV-1 inhibitors that target CCR5 coreceptor function.